Author

Stephen B Hanauer 1

1 Feinberg School of Medicine, Northwestern University,Chicago,United States

BI 695501 DEMONSTRATES SIMILAR EFFICACY AND COMPARABLE SAFETY TO ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH ACTIVE CROHN'S DISEASE: FINAL ANALYSIS OF THE PHASE III VOLTAIRE-CD STUDY

Stephen B Hanauer, Stefan Schreiber, Sigrid Balser, Ekkehard Brockstedt, Dorothy McCabe, Viktoria Moschetti, Bernd Liedert

CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY

Silvio Danese, William Sandborn, Edward V. Loftus Jr., Stephen B Hanauer, Stefan Schreiber, Laurent Peyrin-Biroulet, Remo Panaccione, Julian Panés, Filip Baert, Jean-Frederic Colombel, Marc Ferrante, Edouard Louis, Alessandro Armuzzi, Sasikiran Goteti, John Liu, Nael M. Mostafa, Thao Doan, Joel Petersson, Anne M. Robinson

EFFECTS OF OZANIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: FLOW CYTOMETRY RESULTS FROM THE STEPSTONE PHASE 2 STUDY

Sarah Harris, William Sandborn, Brian G. Feagan, Stephen B Hanauer, Severine Vermeire, Subrata Ghosh, Wenzhong Liu, Douglas C. Wolf, Geert D’Haens

EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN'S DISEASE THROUGH 5 YEARS: FINAL RESULTS FROM THE IM-UNITI LONG-TERM EXTENSION

William Sandborn, Paul Rutgeerts, John Lynch, Rory Rebuck, Yuhua Wang, Bin Zou, Christopher Gasink, Omoniyi J. Adedokun, Bruce E. Sands, Stephen B Hanauer, Stephan Targan, Subrata Ghosh, Willem de Villiers, Jean-Frederic Colombel, Brian G. Feagan

ETROLIZUMAB VERSUS PLACEBO IN TUMOR NECROSIS FACTOR ANTAGONIST NAIVE PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE RANDOMIZED PHASE 3 LAUREL TRIAL

Severine Vermeire, Peter L Lakatos, Timothy Ritter, Stephen B Hanauer, Brian Bressler, Reena Khanna, Kim Isaacs, Saumin Shah, Alysha Khavarian Kadva, Helen Tyrrell, Young Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Wenhui Zhang, Brian G. Feagan

LONG-TERM SAFETY AND EFFICACY OF OZANIMOD IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE TOUCHSTONE OPEN-LABEL EXTENSION

William Sandborn, Brian G. Feagan, Stephen B Hanauer, Severine Vermeire, Subrata Ghosh, Wenzhong Liu, AnnKatrin Petersen, Lorna Charles, Vivian Huang, Keith Usiskin, Douglas C. Wolf, Geert R. D'Haens

OZANIMOD AS INDUCTION THERAPY IN MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY

William Sandborn, Geert R. D'Haens, Douglas C. Wolf, Stephen B Hanauer, Igor Jovanovic, Subrata Ghosh, AnnKatrin Petersen, Steven Y Hua, Ji Hwan Lee, Lorna Charles, Keith Usiskin, Silvio Danese, Brian G. Feagan

OZANIMOD AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRUE NORTH STUDY

Silvio Danese, Brian G. Feagan, Douglas C. Wolf, Stephen B Hanauer, Igor Jovanovic, Subrata Ghosh, AnnKatrin Petersen, Steven Y Hua, Ji Hwan Lee, Lorna Charles, Denesh Chitkara, William Sandborn, Geert D’Haens

THE PHARMACOKINETICS AND IMMUNOGENICITY OF USTEKINUMAB AND ADALIMUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS FROM THE SEAVUE STUDY

Silvio Danese, James Izanec, Tony Ma, Omoniyi J. Adedokun, Christopher Gasink, Stephen B Hanauer, Ellen Scherl, Kamal Patel

Item 1 - 9 / 9
1